
Quiz|Articles|August 23, 2026
Dermatology Times Spot Test: August 23, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A weekly question-based feature is positioned as an ongoing self-assessment tool for clinicians tracking dermatology essentials and emerging science.
- This week’s quiz content targets vitiligo, steering attention to the latest news and developments relevant to clinical conversations.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest news in
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
In the phase 1b trial, how did FB102 perform compared with placebo on mean FVASI improvement at week 24 in the efficacy-evaluable population?
What type of drug is LNK01004?
What did both TRANQUILLO and TRANQUILLO 2 trials of ritlecitinib demonstrate?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Lebrikizumab Pregnancy Study Opens for Atopic Dermatitis
2
Social Media Mythbusters: Exosomes in Skin Care
3
Oral IL-23 Blocker Icotrokinra Brings Biologic-Like Efficacy to Psoriasis
4
ICYMI: FDA Clears RHA Redensity Eye for Infraorbital Hollowing
5











